Abstract
Patients with a metabolic syndrome (overweight, diabetes, hypertension, and dyslipidemia) have a particularly bad outcome if infected with SARS-CoV-2. Yu et al. (2020) suggest that insulin therapy itself may promote fatality in patients with COVID-19 and diabetes.
Copyright © 2020 Elsevier Inc. All rights reserved.
MeSH terms
-
COVID-19 / complications
-
COVID-19 / metabolism*
-
COVID-19 Drug Treatment
-
Diabetes Mellitus, Type 2 / complications
-
Diabetes Mellitus, Type 2 / drug therapy
-
Diabetes Mellitus, Type 2 / metabolism*
-
Female
-
Glucose / metabolism*
-
Humans
-
Inflammation / complications
-
Inflammation / drug therapy
-
Inflammation / metabolism
-
Insulins / adverse effects
-
Insulins / metabolism*
-
Insulins / therapeutic use
-
Male
-
SARS-CoV-2 / metabolism*